CCRM
Jamie Stiff is an experienced professional in the healthcare and biotechnology sectors, currently serving as Managing Director at Genesys Capital since June 2002, focusing on developing emerging life science companies. Jamie holds directorship roles at EBT Medical, Inc., specializing in neuromodulation therapies, and Inversago Pharma, which is working on cannabinoid therapies for metabolic disorders. Additionally, Jamie is involved with multiple organizations, including BIOTECanada, Creative Destruction Lab, CCRM, and the MaRS Investment Accelerator Fund, providing advisory services on investment committees. Educational qualifications include an MBA in life sciences venture capital from the University of Toronto's Rotman School of Management and a Bachelor of Science in Biology/Genetics from Queen's University.
This person is not in any teams
This person is not in any offices
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.